Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Analyst Ratings
Hold
0 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IRWD Stock 12 Month Forecast
Average Price Target
―| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Craig-Hallum
$1.7→$3.8
Hold
85.37%
Upside
Reiterated
11/26/25
Wells Fargo
$1→$3
Hold
46.34%
Upside
Reiterated
11/11/25
Leerink Partners
$1
Hold
-51.22%
Downside
Reiterated
08/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)We continue to await clarity on what the path forward will look like (including handling of the 2026 convert) following disclosure earlier this year that the company would evaluate strategic alternatives. Notably, mgmt. told us they are hoping to share an update within 3Q. Recall, the choice to explore strategic alternatives was driven by eroding commercial fundamentals for leading constipation drug Linzess (collab. w/ a regulatory setback for key pipeline drug apraglutide in short bowel syndrome (SBS) amidst the company’s high debt load. More detail below, including from our mgmt. catch-up. Reiterate MP.
Jefferies
$0.7
Hold
-65.85%
Downside
Downgraded
04/15/25
Citizens JMP
―
Hold
―
Downgraded
04/14/25
UBS
$8→$0.7
Hold
-65.85%
Downside
Downgraded
04/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
$1.7→$3.8
Hold
85.37%
Upside
Reiterated
11/26/25
Wells Fargo
$1→$3
Hold
46.34%
Upside
Reiterated
11/11/25
Leerink Partners
$1
Hold
-51.22%
Downside
Reiterated
08/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)We continue to await clarity on what the path forward will look like (including handling of the 2026 convert) following disclosure earlier this year that the company would evaluate strategic alternatives. Notably, mgmt. told us they are hoping to share an update within 3Q. Recall, the choice to explore strategic alternatives was driven by eroding commercial fundamentals for leading constipation drug Linzess (collab. w/ a regulatory setback for key pipeline drug apraglutide in short bowel syndrome (SBS) amidst the company’s high debt load. More detail below, including from our mgmt. catch-up. Reiterate MP.
Jefferies
$0.7
Hold
-65.85%
Downside
Downgraded
04/15/25
Citizens JMP
―
Hold
―
Downgraded
04/14/25
UBS
$8→$0.7
Hold
-65.85%
Downside
Downgraded
04/14/25
Best Analysts Covering Ironwood Pharma
1 Month
xxx
Success Rate
1/7 ratings generated profit
Average Return
-9.59%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 14.29% of your transactions generating a profit, with an average return of -9.59% per trade.
3 Months
xxx
Success Rate
2/7 ratings generated profit
Average Return
-11.87%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -11.87% per trade.
1 Year
Success Rate
0/11 ratings generated profit
Average Return
-76.78%
reiterated a buy rating last month
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.78% per trade.
2 Years
xxx
Success Rate
0/7 ratings generated profit
Average Return
-83.96%
reiterated a xxx
rating 2 years ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -83.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IRWD Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
13
15
16
11
16
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
14
16
16
11
16
Each month's total comprises the sum of three months' worth of ratings.
IRWD Financial Forecast
IRWD Stock Forecast FAQ
What is IRWD’s average 12-month price target, according to analysts?
Currently, no data Available
What is IRWD’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IRWD, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IRWD a Buy, Sell or Hold?
Ironwood Pharma has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
What is Ironwood Pharma’s price target?
Currently, no data Available
What do analysts say about Ironwood Pharma?
Ironwood Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of IRWD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.